[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Brett A Faine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100569398","phase-4-early-angiotensin-ii-in-the-emergency-department-100569398",false,"NCT06693726","Early Angiotensin II in the Emergency Department","ANGIOtensin II for Septic Shock in the Emergency Department: ANGIO-ED Study","ANGIO-ED","Inclusion Criteria\n\n1. Age ≥18; and\n2. Requiring norepinephrine at a dose of 0.05-0.25 mcg\u002Fkg\u002Fmin mcg\u002Fkg\u002Fminute despite adequate fluid resuscitation; and\n3. Receiving intravenous antibiotics or clinician's intention to administer antibiotics at the time of enrollment; and\n4. Can provide written informed consent (or legally authorized representative).\n\nExclusion Criteria\n\n1. Acute coronary syndrome;\n2. Cardiogenic shock;\n3. Patients with a history of mesenteric ischemia;\n4. Patients with a history of having an aortic dissection or abdominal aortic aneurysm;\n5. Patients with an expected lifespan of \\\u003C12 hours;\n6. Patients with hemorrhagic shock (e.g., actively receiving transfusion of packed red blood cells);\n7. Active administration of two vasoactive agents before enrollment; and\n8. Pre-existing thromboembolic disease or inability to tolerate pharmacologic VTE prophylaxis.","ALL","18 Years","99 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This pilot study will enroll 20 patients with septic shock and require emergent vasopressor support in the emergency department (ED). The primary objective of the study is to determine the feasibility of early peripheral administration of angiotensin II for treatment of septic shock in the ED",[28],"Septic Shock",[30],"Angiotensin II","RECRUITING","2026-09-01",{"date":34,"type":35},"2026-09-02","ACTUAL",{"date":37,"type":35},"2025-04-01",{"date":39,"type":22},"2027-01-30",{"name":41,"class":42},"Brett A Faine","OTHER",""]